5.6.1 Coronavirus
For treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, only if:
they have 1 or more risk factors for progression to severe COVID-19
and
both nirmatrelvir plus ritonavir is contraindicated or unsuitable
(NICE TA1056)
| Pack |
|---|
| 40 capsule |
Nirmatrelvir plus ritonavir is recommended as an option for treating COVID‑19 in adults, only if they:
-
do not need supplemental oxygen for COVID‑19 and
-
have an increased risk for progression to severe COVID‑19, as defined in section 5. (TA878)
| Pack |
|---|
| 30 tablet |
Where more than one biologic treatment is suitable, it is the responsibility of the provider to ensure the most cost-effective option is selected.
Biosimilars are available which should be used in line with local contracting agreements.
Originator - RoActemra
Biosmilar - Avtozma
-
are having systemic corticosteroids and
-
need supplemental oxygen or mechanical ventilation (TA878
| Pack |
|---|
| 4 pre-filled disposable injection |
| Pack |
|---|
| 4 pre-filled disposable injection |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 vial |